公开(公告)号：US20190216882A1

公开(公告)日：2019-07-18

申请号：US16227994

申请日：2018-12-20

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K38/06 ,  A61K31/4184 ,  A61K31/498 ,  A61K31/454 ,  A61K9/24 ,  A61K9/16 ,  A61K9/20 ,  A61K9/14 ,  A61K9/28

CPC classification number: A61K38/06 ,  A61K9/146 ,  A61K9/1688 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2866 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/498 ,  A61K2300/00

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US20160375017A1

公开(公告)日：2016-12-29

申请号：US15212997

申请日：2016-07-18

Applicant: AbbVie Inc.

Inventor： Katharina Asmus ,  Yi Gao ,  Colleen Garrett ,  Harald Hach ,  Adivaraha Jayasankar ,  Kyeremateng Samuel ,  Ute Lander ,  Thomas Mueller ,  Marius Naris ,  Constanze Obermiller ,  Regina Reul ,  Katrin Schneider ,  Nancy Sever ,  Michael Simon ,  Benedikt Steitz ,  Ping Tong ,  Ulrich Westedt ,  Donghua Zhu

IPC: A61K31/498 ,  A61K9/20 ,  A61K9/24 ,  A61K31/454 ,  A61K9/10

CPC classification number: A61K31/498 ,  A61K9/146 ,  A61K9/2027 ,  A61K9/209 ,  A61K31/454 ,  A61K31/4985 ,  A61K2300/00

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract translation: 本发明的特征在于包含化合物1和化合物2的固体药物组合物。在一个实施方案中，固体药物组合物包括（1）包含100mg化合物1的第一层以及药学上可接受的亲水性聚合物和药学上可接受的表面活性剂， 所有这些都配制成无定形固体分散体; 和（2）包含40mg化合物2的第二层，以及药学上可接受的亲水性聚合物和药学上可接受的表面活性剂，所有这些都被配制成无定形固体分散体。

公开(公告)号：US20200253968A1

公开(公告)日：2020-08-13

申请号：US16654442

申请日：2019-10-16

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K31/498 ,  A61K31/454 ,  A61K9/24 ,  A61K9/20 ,  A61K9/14 ,  A61K31/4985

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US20240075026A1

公开(公告)日：2024-03-07

申请号：US18107243

申请日：2023-02-08

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K31/498 ,  A61K9/14 ,  A61K9/20 ,  A61K9/24 ,  A61K31/454 ,  A61K31/4985

CPC classification number: A61K31/498 ,  A61K9/146 ,  A61K9/2027 ,  A61K9/209 ,  A61K31/454 ,  A61K31/4985

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US20160375087A1

公开(公告)日：2016-12-29

申请号：US15192211

申请日：2016-06-24

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K38/06 ,  A61K9/28 ,  A61K9/20 ,  A61K9/16 ,  A61K31/4184 ,  A61K9/24

CPC classification number: A61K38/06 ,  A61K9/146 ,  A61K9/1688 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2866 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/498 ,  A61K2300/00

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US11246866B2

公开(公告)日：2022-02-15

申请号：US16654442

申请日：2019-10-16

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K31/498 ,  A61K9/28 ,  A61K9/20 ,  A61K31/454 ,  A61K9/24 ,  A61K9/14 ,  A61K31/4985

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US20200282004A1

公开(公告)日：2020-09-10

申请号：US16654433

申请日：2019-10-16

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K38/06 ,  A61K9/14 ,  A61K9/20 ,  A61K9/24 ,  A61K31/454 ,  A61K31/498 ,  A61K9/16 ,  A61K9/28 ,  A61K31/4184

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.